RxDoctor Payments Data

Nausheen Abbas, MD

Ophthalmology · West Bend, WINPI 1356665236

Payments from drug & device makers

$1,019in general payments, 2019–2025

Across 38 payments — averaging $26.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$176
  • Sight Sciences, Inc.$149
  • Amgen$113
  • Mallinckrodt Hospital Products Inc.$105
  • AbbVie$79
  • Glaukos Corporation$59
  • plus $338 from 10 others

What the payments were for

  • Food & beverage$99998%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,019 in reported general payments places this provider in the 65th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$123,487
Medicare patients
137
Services billed
929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine140$108,244
Cyclosporine26$11,753
Prednisolone Acetate62$2,613
Fluorometholone30$2,572
Latanoprost222$2,154
Brimonidine Tartrate75$2,105
ValacyclovirValacyclovir Hcl43$1,935
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat118$1,512
Ketorolac Tromethamine30$912
CombiganBrimonidine Tartrate/Timolol11$769
Timolol Maleate75$483
Dorzolamide Hcl20$267
ErythromycinErythromycin Base22$240
Ofloxacin21$212
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$79$109,013151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in West Bend

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →